72 results match your criteria: "Canada. steven.narod@wchospital.ca.[Affiliation]"
Hered Cancer Clin Pract
November 2024
Women's College Research Institute, Women's College Hospital, 76 Grenville Street, Toronto, ON, M5S 1B2, Canada.
Genetic testing for breast cancer predisposing genes has expanded beyond BRCA1 and BRCA2 and now includes panels of 20 or more genes. It is now recommended that all women diagnosed with breast cancer at age 65 or below be offered testing for an extended gene panel. The rationale for testing includes personalizing the management of breast cancer according to the mutation found.
View Article and Find Full Text PDFHered Cancer Clin Pract
May 2024
Women's College Research Institute, Women's College Hospital, 76 Grenville St, M5S 1B1, Toronto, ON, Canada.
Background: It has not been clearly established if skin cancer or melanoma are manifestations of BRCA1 or BRCA2 mutation carrier status. Estimating the risk of skin cancer is an important step towards developing screening recommendations.
Methods: We report the findings of a prospective cohort study of 6,207 women from North America who carry BRCA1 or BRCA2 mutations.
Hered Cancer Clin Pract
November 2023
Women's College Research Institute, University of Toronto, 790 Bay Street, Toronto, ON, Canada.
With widespread testing for susceptibility genes, increasing numbers of women are being identified to carry a mutation in one of many genes which renders them susceptible to cancer. The first gene to be identified (in 1994) was BRCA1 which increases a woman's risk for breast cancer (70%) and ovarian cancer (40%). The prevalence of BRCA1 gene mutations has been studied widely and in many countries, mostly in women affected with cancer.
View Article and Find Full Text PDFBr J Cancer
February 2024
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Background: Risk-reducing mastectomy (RRM) is offered to women with a BRCA1 or BRCA2 pathogenic variant, however, there are limited data on the impact on breast cancer mortality.
Methods: Participants were identified from a registry of women with BRCA1/2 pathogenic variants. We used a pseudo-randomised trial design and matched one woman with a RRM to one woman without a RRM on year of birth, gene, and country.
Breast Cancer Res Treat
September 2023
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Purpose: Chemoprevention with a selective estrogen receptor modulator (tamoxifen or raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast cancer. The evidence for tamoxifen benefit is based on trials conducted among predominantly postmenopausal women from the general population and on studies of contralateral breast cancer in women with a pathogenic variant (mutation hereafter) in BRCA1 or BRCA2. Tamoxifen has not been assessed as a primary prevention agent in women with an inherited BRCA mutation.
View Article and Find Full Text PDFHered Cancer Clin Pract
June 2023
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Br J Cancer
February 2023
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
NPJ Precis Oncol
June 2022
Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Most criteria for genetic testing for prostate cancer susceptibility require a prior diagnosis of prostate cancer, in particular cases with metastatic disease are selected. Advances in the field are expected to improve outcomes through tailored treatments for men with advanced prostate cancer with germline pathogenic variants, although these are not currently offered in the curative setting. A better understanding of the value of genetic testing for prostate cancer susceptibility in screening, for early detection and prevention is necessary.
View Article and Find Full Text PDFBr J Cancer
September 2022
Women's College Research Institute, Women's College Hospital, 76 Grenville Street, Toronto, ON, Canada.
Background: Several clinical and tumour factors impact on ovarian cancer survival. It is important to evaluate if germline mutations impact long-term outcomes among patients with epithelial ovarian cancer.
Methods: We followed 1422 Ontario women with ovarian cancer.
Br J Cancer
July 2022
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Unii Lubelskiej 1 St, 71-252, Szczecin, Poland.
Background: To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation.
Methods: Women with Stage I-III breast cancer who were treated at 17 hospitals in Poland were tested for four founder mutations in the CHEK2 gene. 974 women (10%) were positive for a CHEK2 mutation.
Nat Rev Clin Oncol
October 2021
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Br J Cancer
August 2021
Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Background: We sought to estimate the annual risk and 25-year cumulative risk of contralateral breast cancer among women with stage 0-III unilateral breast cancer.
Methods: We identified 812,851 women with unilateral breast cancer diagnosed between 1990 and 2015 in the SEER database and followed them for contralateral breast cancer for up to 25 years. Women with a known bilateral mastectomy were excluded.
Br J Cancer
April 2021
University of Zielona Góra, Zielona Góra, Poland.
Background: The impact of various breast-cancer treatments on patients with a BRCA2 mutation has not been studied. We sought to estimate the impact of bilateral oophorectomy and other treatments on breast cancer-specific survival among patients with a germline BRCA2 mutation.
Methods: We identified 664 women with stage I-III breast cancer and a BRCA2 mutation by combining five different datasets (retrospective and prospective).
Breast Cancer Res Treat
June 2021
Women's College Research Institute, Women's College Hospital, 76 Grenville Street, 6th Floor, Toronto, ON, M5S 1B2, Canada.
Purpose: It is not known whether the risk of breast cancer among BRCA1 and BRCA2 mutation carriers after age 60 is high enough to justify intensive screening or prophylactic surgery. Thus, we conducted a prospective analysis of breast cancer risk in BRCA1 and BRCA2 mutation carriers from age 60 until age 80.
Methods: Subjects had no history of cancer and both breasts intact at age 60 (n = 699).
Breast Cancer Res Treat
February 2021
Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.
Purpose: Many women with early-onset breast cancer experience adverse psychological sequelae which impact on their quality of life. We sought to correlate levels of anxiety and cancer-related distress in women with breast cancer shortly after surgery and one year after treatment with the estimated risk of death.
Methods: We studied 596 women with Stage I to III breast cancer.
Int J Gynecol Cancer
June 2020
Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada
Introduction: Preventive bilateral salpingo-oophorectomy is the most effective means of reducing the risk of ovarian cancer among women with an inherited or mutation. Some women are diagnosed with an invasive cancer (ovarian or fallopian tube) at the time of preventive surgery, referred to as an 'occult' cancer. The survival experience of these women is not known.
View Article and Find Full Text PDFCancers (Basel)
October 2019
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Bloom Syndrome is a rare recessive disease which includes a susceptibility to various cancers. It is caused by homozygous mutations of the gene. To investigate whether heterozygous carriers of a mutation are predisposed to breast cancer, we sequenced in 617 patients from Polish families with a strong family history of breast cancer.
View Article and Find Full Text PDFBreast Cancer Res Treat
November 2019
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, 71-252, Poland.
Background: NBN 657del5 founder mutation predisposes to breast and prostate cancer. Recently, it has been reported that the pathogenicity of this mutation with regard to prostate cancer risk is modified by a missense variant of the same gene (E185Q).
Methods: To evaluate the interaction of the 657del5 and E185Q founder alleles of NBN on breast cancer risk in Poland, 4964 women with breast cancer and 6152 controls were genotyped for these two recurrent variants of NBN (657del5 truncating variant and E185Q missense variant).
Breast Cancer Res Treat
October 2019
Women's College Research Institute, 76 Grenville Street, Toronto, ON, M5S 1B1, Canada.
Background: Women with ER-positive breast cancer may recur as late as 20 years post-diagnosis. The reason for this delayed recurrence is unknown. We studied survival patterns, including time-to-death in 123,705 women with stage I to III invasive breast cancer, enrolled in the SEER database.
View Article and Find Full Text PDFCancers (Basel)
May 2019
Department of Molecular Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61704 Poznan, Poland.
In addition to several well-established breast cancer (BC) susceptibility genes, the contribution of other candidate genes to BC risk remains mostly undefined. is a potentially predisposing BC gene, however, the rarity of its mutations and an insufficient family/study size have hampered corroboration and estimation of the associated cancer risks. To clarify the role of mutations in BC predisposition, a comprehensive case-control association study of a recurring nonsense mutation c.
View Article and Find Full Text PDFBr J Cancer
July 2019
Women's College Research Institute, Toronto, ON, Canada.
Background: Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer. In the current study, we report on uptake of cancer screening and risk-reduction options in a cohort of BRCA mutation carriers from ten countries over two time periods (1995 to 2008 and 2009 to 2017).
Methods: Eligible subjects were identified from an international database of female BRCA mutation carriers and included women from 59 centres from ten countries.
Hum Genet
March 2019
Women's College Research Institute, Women's College Hospital, 76 Grenville Street, M5S 1B2, Toronto, Ontario, Canada.
The author engages in further debate between numerous signatories of a letter who disputes that the author has put forward that the anticipated benefits of a personalised program for cancer prevention and screening are unwarranted. In the event that a cancer screening program is an effective means of mortality reduction, then the best strategy is universality. The benefit of a novel intervention should be evaluated prior to its introduction.
View Article and Find Full Text PDFBreast Cancer Res Treat
June 2019
Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.
Purpose: Following a diagnosis of breast cancer, BRCA mutation carriers face an increased risk of developing a second (contralateral) cancer in the unaffected breast. It is important to identify predictors of contralateral cancer in order to make informed decisions about bilateral mastectomy. The impact of bilateral salpingo-oophorectomy (i.
View Article and Find Full Text PDFBr J Cancer
February 2019
Women's College Research Institute, Toronto, ON, Canada.
Background: To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer.
Methods: Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation.
Breast Cancer Res Treat
April 2019
Women's College Research Institute, Women's College Hospital, 76 Grenville St., 6th Floor, Toronto, ON, M5S 1B2, Canada.
Purpose: Women with an inherited germline BRCA1 mutation have a high lifetime risk of developing breast cancer. We have previously shown that, among BRCA mutation carriers, incidence rates of breast cancer vary by country of residence.
Methods: In the current study, we prospectively calculated the cumulative and annual incidence rates of incident breast cancer, contralateral breast cancer and ipsilateral breast cancer recurrence among BRCA1 mutation carriers in Poland.